Reduces 30-day risk for hospitalization and death, while only death was reduced in association with molnupiravir
Risk for cardiovascular death and myocardial infarction similar for CCTA and ICA; risk reduced with CCTA compared with exercise ECG, SPECT-MPI
Significant improvement seen in progression-free survival and in time to next intervention for vorasidenib versus placebo